AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 222.58 |
Market Cap | 46.45B |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | 7.53 |
PE Ratio (ttm) | 31.92 |
Forward PE | n/a |
Analyst | Buy |
Ask | 248 |
Volume | 917,928 |
Avg. Volume (20D) | 1,235,440 |
Open | 237.69 |
Previous Close | 236.09 |
Day's Range | 235.89 - 240.63 |
52-Week Range | 214.77 - 253.27 |
Beta | undefined |
About COR
Cencora, Inc. sources and distributes pharmaceutical products. Its U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers. The company also provides pha...
Analyst Forecast
According to 10 analyst ratings, the average rating for COR stock is "Buy." The 12-month stock price forecast is $282.5, which is an increase of 17.55% from the latest price.
Next Earnings Release
Analysts project revenue of $78.22B, reflecting a 8.26% YoY growth and earnings per share of 3.51, making a 7.01% increase YoY.